198 related articles for article (PubMed ID: 17592497)
1. Histone modifications as markers of cancer prognosis: a cellular view.
Kurdistani SK
Br J Cancer; 2007 Jul; 97(1):1-5. PubMed ID: 17592497
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
3. Histone modifications and cancer.
Sawan C; Herceg Z
Adv Genet; 2010; 70():57-85. PubMed ID: 20920745
[TBL] [Abstract][Full Text] [Related]
4. Histone onco-modifications.
Füllgrabe J; Kavanagh E; Joseph B
Oncogene; 2011 Aug; 30(31):3391-403. PubMed ID: 21516126
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
6. [The significance of histone modifications in malignant transformation].
Gomulak P; Błasiak J
Postepy Biochem; 2012; 58(3):292-301. PubMed ID: 23373415
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic gene regulation in cancer.
Ballestar E; Esteller M
Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
[TBL] [Abstract][Full Text] [Related]
8. [Epigenome and cancer: new possibilities of cancer prevention and therapy?].
Paluszczak J; Baer-Dubowska W
Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the cancer imprintome.
Monk D
Brief Funct Genomics; 2010 Jul; 9(4):329-39. PubMed ID: 20551091
[TBL] [Abstract][Full Text] [Related]
10. [Acquired disorders and epigenetics].
Ushijima T
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1645-9. PubMed ID: 20841925
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
Bhalla KN
J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
[TBL] [Abstract][Full Text] [Related]
12. Interplay between different epigenetic modifications and mechanisms.
Murr R
Adv Genet; 2010; 70():101-41. PubMed ID: 20920747
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation and histone modification regulate silencing of OPG during tumor progression.
Lu TY; Kao CF; Lin CT; Huang DY; Chiu CY; Huang YS; Wu HC
J Cell Biochem; 2009 Sep; 108(1):315-25. PubMed ID: 19565568
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic biomarkers for human cancer: the time is now.
Mulero-Navarro S; Esteller M
Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
[TBL] [Abstract][Full Text] [Related]
15. Cancer epigenetics.
Taby R; Issa JP
CA Cancer J Clin; 2010; 60(6):376-92. PubMed ID: 20959400
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the epigenetic code of cancer for therapy.
Smith LT; Otterson GA; Plass C
Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells.
Vincent A; Perrais M; Desseyn JL; Aubert JP; Pigny P; Van Seuningen I
Oncogene; 2007 Oct; 26(45):6566-76. PubMed ID: 17471237
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic changes in solid and hematopoietic tumors.
Toyota M; Issa JP
Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetics and cancer].
Xue C; Yu J; Liu H; Chen J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Oct; 26(5):1133-6. PubMed ID: 19947505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
